Effects of peroxisome proliferator-activated receptor-α and -γ agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats

British Journal of Pharmacology

Volumn 130, Issue 3, 2000, Pages 495-504

  Shibata, Tsutomu ^a   Takeuchi, Satomi ^a   Yokota, Seiko ^a   Kakimoto, Kochi ^a   Yonemori, Fumihiko ^a   Wakitani, Korekiyo ^a  

^a JAPAN TOBACCO INC   (Japan)

Author keywords

Diabetic complication; JTT 501; Peroxisome proliferator activated receptor (PPAR) and PPAR agonist; Troglitazone; Zucker diabetic fatty (ZDF) rat

Indexed keywords

ANTIDIABETIC AGENT; CHOLESTEROL; NOSCAPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; RECEPTOR SUBTYPE; REGLITAZAR; TROGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE TURNOVER; CATARACT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; HYPERGLYCEMIA; HYPERLIPIDEMIA; MALE; NONHUMAN; OBESITY; OSTEOPENIA; PATHOGENESIS; PRIORITY JOURNAL; RAT; RAT STRAIN;

EID: 0034109448     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703328     Document Type: Article

References (41)

1. BARRETT-CONNOR, E. & KRITZ-SILVERSTEIN, D. (1996). Dose hyperinsulinemia preserve bone? Diabetes Care, 19, 1388-1392.
2. CLARK, J.B., PALMER, C.J. & SHAW, W.N. (1983). The diabetic Zucker fatty rat (41611). Proc. Soc. Exp. Biol. Med., 173, 68-75.
3. CORNISH, J., GALLON, K.E. & REID, I.R. (1996). Insulin increases histomorphometric indices of bone formation in vivo. Calcif. Tissue Int., 59, 492-495.
4. DANIS, R.P. & YANG, Y. (1993). Microvascular retinopathy in the Zucker diabetic fatty rat. Invest. Ophthalmol. Vis. Sci., 34, 2367-2371.
5. DESVERGNE, B., IJPENBERG, A., DEVCHAND, P.R. & WAHLI, W. (1998). The peroxisome proliferator-activated receptors at the cross-road of diet and hormonal signalling. J. Steroid. Biochem. Molec. Biol., 65, 65-74.
6. FUKUNAGA, Y., MINAMIKAWA, J., INOUE, D. & KOSHIYAMA, H. (1997). Dose insulin use increase bone mineral density in patients with non-insulin-dependent diabetes mellitus? Arch. Intern. Med., 157, 2668-2669.
7. HANSSEN, K.F. (1991). The determinants of microvascular compl cations in diabetes: an overview. In Textbook of Diabetes, ed Pickup, J.C. and Williams, G. pp. 519-525. Oxford: Blackwell Scientific Publications.
8. HANSSEN, K.F. (1997). Blood glucose control and microvascular and macrovascular complications in diabetes. Diabetes, 46, (Suppl. 2), S101-S103.
9. HOTTA, N., NAKAMURA, J., KAKUTA, H., FUKASAWA, H., KOH, N., SAKAKIBARA, F., MORI, K. & SAKAMOTO, N. (1995). Niceritrol prevents the decrease in red blood cell 2,3-diphosphoglycerate and neuropathy in streptozotocin-induced diabetic rats. J. Diab. Comp., 9, 133-139.
10. HUI, S.L., EPSTEIN, S. & JOHNSTON, C.C. (1985). A prospective study of bone mass in patients with Type 1 diabetes. J. Clin. Endocrinol. Metab., 60, 74-80.
11. ISHIDA, H., SEINO, Y., MATSUKURA, S., IKEDA, M., YAWATA, M., YAMASHITA, G., ISHIZUKA, S. & IMURA, H. (1985). Diabetic osteopenia and circulating levels of vitamin D metabolites in type 2 (noninsulin-dependent) diabetes. Metabolism, 34, 797-801.
12. ITUARTE, E.A., HALSTEAD, L.R., IIDA-KLEIN, A., ITUARTE, H.G. & HAHN, T.J. (1989). Glucose transport system in UMR-106-01 osteoblastic osteosarcoma cells: regulation by insulin. Calcif. Tissue Int., 45, 27-33.
13. JOHNSTON, C.C., HUI, S.L. & LONGCOPE, C. (1985). Bone mass and sex steroid concentrations in postmenopausal caucasian diabetes. Metabolism, 34, 544-550.
14. KELLER, H., DREYER, C., MEDIN, J., MAHFOUDI, A., OZATO, K. & WAHLI, W. (1993). Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc. Natl. Acad. Sci. U.S.A., 90, 2160-2164.
15. KLEIN, R. (1995). Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care, 18, 258-268.
16. LEIVIN, M.E., BOISSEAU, V.C. & AVIOLI, L.V. (1976). Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes. N. Engl. J. Med., 294, 241-245.
17. MAEGAWA, H., OBATA. T., SHIBATA, T., FUJITA, T., UGI, S., MORINO, K., NISHIO, Y., KOJIMA, H., HIDAKA, H., HANEDA, M., YASUDA, H., KIKKAWA, R. & KASHIWAGI, A. (1999). A new antidiabetic agent (JTT-501) rapidly stimulates glucose disposal rates by enhancing insulin signal transduction in skeleral muscle. Diabelologia, 42, 151 - 159.
18. MIYOSHI, T. &GOTO, I. (1973). Serial in vivo determinations of nerve conduction velocity in rat tails: physiological and pathological changes. Electroencephalogr. Clin. Neurophysio!., 35, 125-131.
19. OHKUBO, Y., KISHIKAWA, H., ARAKI, E., MIYATA, T., ISAMI, S., MOTOYOSHI, S., KOJIMA, Y., FURUYOSHI, N. &SHICHIRI, M. (1995). Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Prac., 28, 103-117.
20. OHNEDA, M., INMAN, L.R. & UNGER, R.H. (1995). Caloric restriction in obese pre-diabetic rats prevents beta-cell depletion, loss of beta-cell GLUT 2 and glucose incompetence. Diabetologia, 38, 173-179.
21. OKUNO, Y., NISHIZAWA, Y., SEKITA, K., HAGIWARA, S., MIKI, T. & MORII, H. (1991). Total and regional bone mineral content in patients with non-insulin dependent diabetes mellitus. J. Nutr. Sci. Vitaminol., 37, S43-S49.
22. PETERSON, R.G., NEEL, M.A., LITTLE, L.A., KINCAID, J.C. & EICHBERG, J. (1990a). Neuropathic complications in the Zucker diabetic fatty rat (ZDF/Drt-fa). In Frontiers in diabetic research. Lesson from animal diabetes III., ed. Shafrir, E., pp. 456-458. London: Smith-Gordon.
23. PETERSON, R.G., SHAW, W.N., NEEL, M.A., LITTLE, L.A. & EICHBERG, J. (1990b). Zucker diabetic fatty rat as a model for non-insulin-dependent diabetes mellitus. ILAR News, 32, 16-19.
24. PIEPKORN, B., KANN, P., FORST, T., ANDREAS, J., PFÜTZNER, A. & BEYER, J. (1997). Bone mineral density and bone metabolism in diabetes mellitus. Horm. Metab. Res., 29, 584-591.
25. REID, I.R., EVANS, M.C., COOPER, G.J.S., AMES, R.W. & STAPLETON, J. (1993). Circulating insulin levels are related to bone density in normal postmenopausal women. Am. J. Physiol., 265, E655-E659.
26. SALTIEL, A.R. & OLEFSKY, J.M. (1996). Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes, 45, 1661-1669.
27. SHIBATA, T., MATSUI, K., NAGAO, K., SHINKAI, H., YONEMORI, F. & WAKITANI, K. (1999). Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative. Eur. J. Pharmacol., 364, 221-219.
28. SHIBATA, T., MATSUI, K., YONEMORI, F. & WAKITANI, K. (1998). JTT-501, a novel antidiabetic agent, improves insulin resistance in genetic and non-genetic insulin-resistant models. Br. J. Pharmacol., 125, 1744-1750.
29. vy/a). Diabetes, 41, 187-193.
30. STURIS, J., PUGH, W.L., TANG, J. & POLONSKY, K.S. (1995). Prevention of diabetes does not completely prevent insulin secretory defects in the ZDF rat. Am. J. Physiol., 269, E786-E792.
31. TERASAKI, J., ANAI, M., FUNAKI, M., SHIBATA, T., INUKAI, K., OGIHARA, T., ISHIHARA, H., KATAGIRI, H., ONISHI, Y., SAKODA, H., FUKUSHIMA, Y., YAZAKI, Y., KIKUCHI, M., OKA, Y. & ASANO, T. (1998). Role of JTT-501, a new insulin sensitiser, in restoring impaired GLUT4 translocation in adipocytes of rats fed a high fat diet. Diabetologia, 41, 400-409.
32. THE DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med., 329, 977-986.
33. THOMAS, D.M., UDAGAWA, N., HARDS, D.K., QUINN, J.M.W., MOSELEY, J.M., FINDLAY, D.M. & BEST, J.D. (1998). Insulin receptor expression in primary and cultured osteoclast-like cells. Bone, 23, 181-186.
34. TOKUYAMA, Y., STURIS, J , DEPAOLI, A.M., TAKEDA, J., STOFFEL, M., TANG, J., SUN, X., POLONSKY, K.S. & BELL, G.I. (1995). Evolution of β-cell dysfunction in the male Zucker diabetic fatty rat. Diabetes, 44, 1447-1457.
35. UK PROSPECTIVE DIABETES STUDY GROUP. (1998a). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352, 837-853.
36. UK PROSPECTIVE DIABETES STUDY GROUP. (1998b). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 352, 854-865.
37. UNGER, R.H. (1991). Role of impaired glucose transport by β cells in the pathogenesis of diabetes. J. NIH Res., 3, 77-80.
38. VAN DAELE, P.L.A., STOLK, R.P., BURGER, H., ALGRA, D., GROBBEE, D.E. HOFMAN, A., BIRKENHÄGER, J.C & POLS, H.A.P. (1995). Bone density in non-insulin-dependent diabetes mellitus.: The Rotterdam Study. Ann. Intern. Med., 122, 409-414.
39. WAKASUGI, M., WAKAO, R., TAWATA, M., GAN, N., KOIZUMI, K. & ONAYA, T. (1993). Bone mineral density measured by dual energy xray absorptiometry in patients with non-insulin-dependent diabetes mellitus. Bone, 14, 29-33.
40. WEINSTOCK, R.S., GOLAND, R.S., SHANE, E., CLEMENS, T.L., LINDSAY, R. & BILEZIKIAN, J.P. (1989). Bone mineral density in women with type II diabetes mellitus. J. Bone Miner. Res., 4, 97-101.
41. WISKE, P.S., WENTWORTH, S.M., NORTON, J.A., EPSTEIN, S. & JOHNSTON, C.C. (1982). Evaluation of bone mass and growth in young diabetes. Metabolism, 31, 848-854.